

Sveinn Sölvason, President and CEO, comments:

"Sales in Q3 2025 amounted to USD 237 million, representing 11% reported growth, of which 7% was organic. Growth picked up in the third quarter as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. The solid momentum in EMEA continues and growth in Americas was strong following a soft start to the year, supported by our recently launched innovations such as Navii, Icon, and Pro-Flex Terra.

Sales in our Bracing & Supports and Patient Care segments remained soft with flat sales in Bracing & Supports and modest growth in Patient Care. At the end of August, we closed the majority investment in Streifeneder ortho.production, which positions us as a full-range provider with opportunities to strengthen our presence in our key O&P markets and expand our offerings and reach in Emerging Markets.

The EBITDA margin was strong at 22% in Q3 2025 and 21% for the first nine months of the year compared to 20% in the comparable period. In line with our performance recorded in the first nine months of 2025, our guidance for the full-year 2025 has been reiterated."

Highlights Q3 2025

- Sales amounted to USD 237 million for the quarter and organic growth was 7 and 11% reported growth (USD growth).
- Prosthetics & Neuro Orthotics (P&NO) sales grew by 13% organic, Bracing & Supports sales were flat, and Patient Care grew 1%.
- Gross profit margin was 63% for the quarter, on par with Q3 2024. For 9M 2025 the gross profit margin increased to 63% compared to 62% in the same period 2024 (63% of sales excl. special items). The gross profit margin in the quarter was positively impacted by strong performance in P&NO coupled with solid efficiency gains in manufacturing. Adversely, the margin was negatively impacted by softer sales in Bracing & Supports and Patient Care and some impact from US tariffs.
- EBITDA was USD 53 million, and EBITDA margin was 22% of sales, on par with Q3 2024. EBITDA margin for 9M 2025 was 21% compared to 20% before special items in 9M 2024. The EBITDA margin in the quarter was positively impacted from strong sales in P&NO combined with solid manufacturing efficiency and continued cost discipline in SG&A. FX negatively impacted EBITDA margin by around 50 basis points in Q3.
- Net profit was USD 26 million and grew by 17%, corresponding to 11% of sales in Q3 2025, compared to 10% in Q3 2024.
- Free cash flow amounted to USD 38 million or 16% of sales, compared to 15% of sales in Q3 2024. Free cash flow was strong and positively impacted by solid operating results, positive impact from net working capital and CAPEX in line with normalized levels.
- NIBD/EBITDA before special items was 2.5x at the end of Q3 2025. The leverage ratio is within the target range of 2.0-3.0x and the share buyback program is ongoing. Embla Medical bought back 525,733 shares for approximately USD 2.7 million in Q3.

Other highlights

- On August 29, 2025, Embla Medical announced the closing of the majority share investment (51% of the shares) in privately owned Streifeneder ortho.production GmbH, an international developer and supplier of orthopedic mobility solutions, employing around 100 people, with sales of EUR 25 million in 2024 (USD 29 million).
- In connection with the investment in Streifeneder ortho.production, Embla Medical issued 2,805,135 new shares on September 5, 2025. The total value of the issued shares amounted to DKK 93 million (USD 14.5 million), which the sellers subscribed to.
- Launch of Odyssey® iQ, a new microprocessor foot by College Park. Odyssey® iQ is a new hydraulically dampened, lightweight, and low-profile foot solution suitable for various environments and activities offering long-lasting battery, and fast responses.

2025 Outlook

- Organic sales growth guidance is unchanged at 5-6%.
- EBITDA margin before special items guidance is unchanged at 20-21%.

	9M 2025	9M 2024	Q3 2025	Q3 2024	Guidance (current)	Guidance (previously)
Sales growth, organic	5%	7%	7%	7%	5-6%	5-6%
EBITDA margin, before special items	21%*	20%	22%	22%	20-21%*	20-21%*

*Potential impact from US trade tariffs continues to be an uncertain element to quantify given the frequent changes in the global tariff environment. Consequently, we deem it too speculative to quantify and guide an exact impact from potential tariffs on Embla Medical's financial results, but some absorption of tariffs is assumed in the guidance.

USD millions	Q3 2025	Q3 2024	9M 2025	9M 2024	FY 2024	FY 2023	FY 2022	FY 2021
Income Statement								
Net sales	237	214	672	630	855	786	719	719
Gross profit	148	134	420	393	535	486	440	455
Operating expenses (excl. other income / exp.)	111	101	328	312	422	398	373	360
EBITDA	53	47	138	123	169	139	114	149
EBITDA before special items	53	47	138	127	173	139	128	149
EBIT	37	33	93	81	113	89	65	97
Net profit	26	22	59	50	69	59	43	66
Sales Growth								
Sales growth USD	% 11	11	7	9	9	9	0	14
Growth breakdown:								
Organic growth	% 7	7	5	7	6	9	4	10
Currency effect	% 3	0	1	0	0	(1)	(7)	3
Acquired business	% 1	3	0	3	3	1	3	1
Balance Sheet								
Total assets	1,722	1,583	1,722	1,583	1,539	1,386	1,325	1,247
Equity	870	787	870	787	781	705	636	627
Net interest-bearing debt (NIBD)	460	460	460	460	414	395	404	363
Cash Flow								
Cash generated by operations	58	52	115	106	160	126	92	128
Free cash flow	38	33	58	43	77	52	35	74
Key Ratios								
Gross profit margin	% 63	63	63	62	63	62	61	63
EBIT margin	% 16	15	14	13	13	11	9	14
EBITDA margin	% 22	22	21	19	20	18	16	21
EBITDA margin before special items	% 22	22	21	20	20	18	18	21
Equity ratio	% 51	50	51	50	51	51	48	50
Net debt to EBITDA before special items*	2.5	2.8	2.5	2.8	2.4	2.8	3.2	2.4
Effective tax rate	% 24	22	24	23	24	23	23	24
Return on equity*	% 9	9	9	9	9	9	7	11
CAPEX / Net sales	% 3.3	4.1	3.6	5.0	4.6	5.4	3.6	3.7
Market								
Market value of equity	2,091	1,991	2,091	1,991	2,125	1,713	2,035	2,724
Number of shares in millions	430	428	430	428	428	421	423	423
Basic EPS in US cents	6.0	5.1	13.8	11.8	16.2	14.0	10.3	15.6
Diluted EPS in US cents	6.0	5.1	13.8	11.8	16.2	14.0	10.3	15.5

Management's report

Financial performance

Sales

Sales increased by 7% organic in Q3 2025

Sales in 9M 2025 amounted to USD 672 million, compared to USD 630 million in 9M 2024, corresponding to 5% organic growth and a 7% reported growth (USD growth). Sales in Q3 2025 amounted to USD 237 million, compared to USD 214 million in Q3 2024, corresponding to 7% organic growth and 8% increase including acquisitions (local currency growth) and 11% reported growth (USD growth).

Positive FX impact of USD 6 million in Q3 2025

Effects from FX amounted to USD 6 million, which positively impacted growth in local currencies by 3%-points, while acquisitions contributed positively by 1%-point for the quarter.

Sales by geographical segment (USD million)	Q3 2025	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth	9M 2025	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth
EMEA	112	7%	2%	7%	16%	327	7%	1%	3%	11%
Americas	104	5%	0%	0%	5%	291	2%	0%	0%	2%
APAC	20	18%	0%	(2%)	16%	54	11%	0%	(3%)	8%
Total	237	7%	1%	3%	11%	672	5%	0%	1%	7%

Sales by business segment (USD million)	Q3 2025	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth	9M 2025	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth
Prosthetics & Neuro Orthotics	135	13%	2%	4%	18%	372	10%	1%	1%	12%
Bracing & Supports	38	0%	0%	2%	1%	111	(1%)	0%	0%	(1%)
Internal product sales	(10)	2%	0%	9%	11%	(29)	1%	0%	2%	3%
External sales	163	10%	2%	3%	14%	455	8%	1%	1%	9%
Patient Care	74	1%	0%	3%	4%	217	0%	0%	2%	2%
Total	237	7%	1%	3%	11%	672	5%	0%	1%	7%

Strong growth in Q3 2025 across all regions driven by P&NO

Growth in Q3 2025 was driven by solid volume growth across all regions in Prosthetics & Neuro Orthotics (P&NO).

Sales growth in the EMEA region was strong in the third quarter with 7% organic growth. In P&NO the strong growth momentum seen over several quarters continued across the European markets in the third quarter. Growth was driven by solid uptake across most product categories, especially in our Bionics and Feet solutions supported by recent innovations such as Navii (bionic knee) and Pro-Flex Terra (mechanical feet solution). Sales in Bracing & Supports in EMEA were soft during the quarter, while sales performance in Patient Care varied across markets.

In Americas sales increased by 5% organic in Q3, driven by a strong recovery in the region following a slower than expected start to the year. Growth is supported by strong uptake across key product categories, including Bionics and recently launched innovations such as the Odyssey iQ (bionic foot) from College Park, which is off to a good start. Sales in Bracing & Supports came in flat and sales in our Patient Care business came in short for the quarter with mixed performance across markets.

In APAC our organic sales growth was very strong with 18% in Q3 2025. Growth is supported by very solid performance in P&NO across markets driven by China, Japan, and Australia. Also, Patient Care demonstrated strong growth for the quarter. Sales in Bracing & Supports was modest in Q3 2025 with solid growth in Australia and New Zealand, but soft performance across most other markets, except Korea, which is recovering on the back of a prolonged Doctor's strike.

In Neuro Orthotics (Fior & Gentz) the business is tracking in line with expectations. Since last year the focus of our Neuro Orthotics strategy is to expand into new international markets, while maintaining the growth momentum in our existing German business. During Q3 we have seen good ramp up in new markets and recently Fior & Gentz was awarded a new reimbursement code in the United States for their bionic knee joint, a significant milestone for the introduction of neuro orthotics in the United States.

The Patient Care market is estimated to grow in the range of 3-5% while yielding healthy operating margins. Our Patient Care business has over the last few quarters experienced lower than expected growth, mainly in EMEA and Americas regions. The performance can partly be ascribed to softness and timing in patient volumes; however, our Patient Care business has been delivering below market growth. The recent weaknesses can be ascribed to internal change initiatives including the ForMotion rebranding rollout, platform-wide integration of new ERP and operational systems, and other change management initiatives impacting ways of operating. This in turn has led to a temporary negative impact on performance in Patient Care, impacting revenue and profitability. The management team's full focus is currently on performance management in order to get the Patient Care business back on track, so the business area can begin to benefit from the structural growth in the O&P industry our product business has recently observed.

As communicated previously, we expect to see a gradual uptake of eligible K2 patients in Americas as prosthetists are gaining experience from fitting the first patients and submitting reimbursement claims. In this context, we expect our recently launched bionic knees Navii® by Össur and Icon® by College Park to address some of the active K2 amputees consistent with the coverage standards published by Medicare. We have so far received encouraging feedback among clinicians and users on our launches and will continue our efforts to enable more active K2 functional level amputees to gain access to advanced bionic knee technology, which previously was restricted to functional level K3 and K4 users.

**Gross profit
margin of 63%
in Q3 2025**

Operations

Gross profit in Q3 2025 amounted to USD 148 million or 63% of sales, compared to USD 134 million or 63% of sales in Q3 2024. Gross profit for 9M 2025 amounted to USD 420 million or 63% of sales, compared to USD 393 million or 62% for the same period last year (63% before special items).

The gross profit margin in the quarter was positively impacted by the strong performance in P&NO combined with solid efficiency in manufacturing. The margin was however negatively impacted by softer sales in Bracing & Supports and Patient Care resulting in less scale in addition to some impact from US tariffs.

**OPEX ratio of
47% in Q3 2025**

Operating expenses (OPEX)

OPEX amounted to USD 111 million or 47% of sales in Q3 2025, compared to USD 101 million or 47% of sales in Q3 2024. For 9M 2025 OPEX amounted to USD 328 million or 49% of sales, compared to USD 312 million or 49% of sales for the same period in 2024.

OPEX growth was 5% organic in the quarter, compared to organic sales growth of 7% with continued focus on cost management in SG&A.

**EBITDA margin
of 22% in Q3
2025**

EBITDA

EBITDA amounted to USD 53 million or 22% of sales in Q3 2025, compared to EBITDA of USD 47 million or on par relative to sales in Q3 2024. For 9M 2025 EBITDA amounted to USD 138 million or 21% of sales, compared to EBITDA of 123 million or 19% of sales for 9M 2024 (20% before special items). EBITDA margin was negatively impacted by around 50 basis points (net of hedge) in Q3, and the FX impact was neutral YTD (net of hedge).

Financial items

Net financial expenses in Q3 2025 amounted to USD 4 million, compared to USD 5 million in Q3 2024. Net financial expenses in 9M 2025 amounted to USD 21 million, compared to USD 18 million for 9M 2024.

Net financial expenses are elevated in the nine-month period due to a negative impact from non-cash currency fluctuations mainly impacting the first half of the year. The impact is negative by USD 6 million in 9M 2025 (positive USD 1.5 million in Q3 2025), compared to negative USD 1 million in 9M 2024 (USD 0.5 million in Q3 2024).

Effective tax rate of 24% in Q3 2025

Income tax

Income tax amounted to USD 8 million in Q3 2025, corresponding to a 24% effective tax rate, compared to USD 6 million in Q3 2024, corresponding to a 22% effective tax rate. For 9M 2025 income tax amounted to USD 18 million, corresponding to a 24% effective tax rate, compared to USD 15 million in 9M 2024, corresponding to a 23% effective tax rate.

Net profit margin of 11% in Q3 2025

Net profit

Net profit grew by 17% in Q3 2025, amounting to USD 26 million or 11% of sales, compared to USD 22 million or 10% of sales in Q3 2024. For 9M 2025 net profit grew by 17% and amounted to USD 59 million or 9% of sales, compared to USD 50 million or 8% of sales for 9M 2024.

Diluted earnings per share in Q3 2025 amounted to 6 US cents, compared to 5.1 in Q3 2024. For 9M 2025 diluted earnings per share amounted to 13.8 US cents, compared to 11.8 for the same period 2024.

Cash flow

Cash generation of USD 58 million in Q3 2025

Cash generated by operations

Cash generated by operations amounted to USD 58 million or 24% of sales in Q3 2025, compared to USD 52 million or 24% of sales in Q3 2024. Cash generated by operations amounted to USD 115 million or 17% of sales in 9M 2025, compared to USD 106 million or 17% of sales in 9M 2024.

Cash generation was strong, supported by solid operating results coupled with positive impact from net working capital.

CAPEX was 3% of sales in Q3 2025

Capital expenditures

Capital expenditures in Q3 2025 amounted to USD 8 million or 3% of sales, compared to USD 9 million or 4% of sales in Q3 2024. Capital expenditures in 9M 2025 amounted to USD 24 million or 4% of sales, compared to USD 31 million or 5% of sales in 9M 2024.

CAPEX in the quarter is in line with normalized levels and the guided range of 3-4% of sales.

Free cash flow was 16% of sales in Q3 2025

Free cash flow

Free cash flow in Q3 2025 amounted to USD 38 million or 16% of sales, compared to USD 33 million or 15% of sales in Q3 2024. Free cash flow in 9M 2025 amounted to USD 58 million or 9% of sales, compared to USD 43 million or 7% of sales in 9M 2024.

Free cash flow was positively impacted by strong operating results coupled with positive impact from net working capital and CAPEX in line with normalized levels.

Cash and undrawn facilities amount to USD 191 million

Bank balances and cash equivalents

Bank balances and cash equivalents amounted to USD 102 million at the end of Q3 2025 and USD 89 million of existing facilities were undrawn. Bank balances and cash equivalents in addition to undrawn credit facilities at the end of Q3 2025, therefore, amounted to USD 191 million.

Capital structure

Net-interest bearing debt

**NIBD/EBITDA
before special
items at 2.6x**

Net interest-bearing debt, including lease liabilities, amounted to USD 460 million at quarter-end Q3 2025 which is flat with the level report in Q3 2024. Net interest-bearing debt to EBITDA before special items corresponded to 2.5x at quarter-end Q3 2025, within the target range of 2.0-3.0x.

Share buybacks and treasury shares

**Share buybacks
of USD 2.7
million in Q3
2025**

The purpose of the program is to reduce the Company's share capital and adjust the capital structure with a desired capital level of 2.0-3.0x net interest-bearing debt to EBITDA before special items, by distributing capital to shareholders in line with the Company's Capital Structure and Capital Allocation Policy.

During Q3 2025, Embla Medical bought back 525,733 shares at a market value of USD 2.7 million. At the end of Q3 2025, treasury shares totaled 2,150,657.

2025 Financial Guidance

Guidance	Guidance FY 2025 (Oct)	Guidance FY 2025 (July)	Guidance FY 2025 (April)	Guidance FY 2025 (Feb)
Sales growth, organic	5-6%	5-6%	5-8%	5-8%
EBITDA margin before special items	20-21%	20-21%	20-21%	20-21%
For modelling purposes				
CAPEX as % of sales	3-4%	3-4%	3-4%	3-4%
Effective tax rate	23-24%	23-24%	23-24%	23-24%

In line with the performance recorded in both Q3 and for the first nine months of 2025, our guidance for the full year 2024 has been reiterated.

As previously communicated, we continue to expect the second half of 2025 to be stronger than the first half of the year, driven by strong performance in our Prosthetics segment across regions and supported by solid growth in the core business and recently launched innovation.

In Neuro Orthotics (Fior & Gentz) we expect the international expansion to new markets to continue to contribute to growth leveraging the Embla Medical/Össur global commercial infrastructure and the ForMotion footprint within O&P clinics.

In Patient Care, we expect growth to improve over the modest performance recorded in the first nine months of the year. We are taking measures to improve our operations, and our current focus is dedicated to performance management to get our Patient Care business back on track. We believe our Patient Care business should be able to benefit better from the structural growth in the O&P industry our product business has recently observed.

Lastly, Bracing & Supports is expected to grow approximately in line with market growth realizing that the market for Bracing & Support remains challenging due to lower patient volumes for elective procedures as well as we have seen increased competitive/price pressure in selected markets.

The guidance for EBITDA margin before special items remain unchanged and is expected to be in the range of 20-21% for 2025. The EBITDA margin is expected to be positively impacted by strong sales performance, a favorable product mix from high-end solutions, continued efficiency gains in manufacturing, and cost discipline in SG&A. The investment in Streifeneder ortho.production GmbH, which was closed at the end of August 2025, is not expected to have a material impact on our financial guidance for 2025.

Potential impact from US trade tariffs

Potential impact from US trade tariffs continues to be an uncertain element to quantify given the frequent changes in the global tariff environment. Consequently, we deem it too speculative to quantify and guide an exact impact from potential tariffs on Embla Medical's financial results. Although, some absorption of tariffs is assumed in the guidance.

As previously communicated, we expect the main impact would be on our Bracing & Supports products manufactured in China and sold in the US. It is our expectation that adjustments could be made to our manufacturing setup to mitigate a large part of additional direct cost.

Foreign exchange

Sales are particularly exposed to fluctuations in the EUR/USD exchange rate. Additionally, the ISK has a relatively high impact on operating results as part of manufacturing, R&D and some corporate functions are based in Iceland, while sales in ISK are minimal. A breakdown of sales and costs by main currencies can be found in note 4 of the accompanying Condensed Consolidated Financial Statements.

All else being equal, a +/- 5% movement in EUR/USD is estimated to have an annual impact on EBITDA in the range of +/- USD 3.5-4.5 million when unhedged. The same movement in ISK/USD is estimated to have an annual impact on EBITDA in the range of +/- USD 3.5-4.5 million when unhedged. Embla Medical utilizes forward contracts to hedge approximately 50% of the estimated net currency exposure in ISK.

Currency overview USD	EUR	ISK
Average exchange rate FY 2024	1.082	0.0073
Average exchange rate in Q1 2025	1.052	0.0072
Average exchange rate in Q2 2025	1.135	0.0078
Average exchange rate in Q3 2025	1.169	0.0082
Opening rate October 20 2025	1.168	0.0082
Estimated average exchange rate for FY 2025*	1.131	0.0076
Change in estimated exchange rate FY 2025 compared to last year's average	5%	4%

*Estimated average exchange rate is calculated as the exchange rate of 9M combined with the exchange rate (open) on Oct 20 2025 for the remainder of the year

Other highlights

Acquisition of Streifeneder ortho.production

On August 29, 2025, Embla Medical announced the closing of a majority share investment (51% of the shares) in privately owned Streifeneder ortho.production GmbH.

Streifeneder ortho.production is an international developer and supplier of orthopaedic mobility solutions, employing around 100 people. In addition to its offerings of prosthetic and orthotic components, Streifeneder ortho.production also supplies orthopaedic materials and equipment to the O&P industry. The investment in Streifeneder represents an attractive opportunity for Embla Medical to become a full range provider to a larger part of the global O&P market, ultimately reaching more patients.

In 2024, Streifeneder ortho.production sales of EUR 25 million (approximately USD 29m) with ~70% of sales related to prosthetics and orthopaedic materials. The majority of sales are generated in Germany, while also selling into other key European markets and distributing into the Americas and APAC regions.

In connection with the investment in Streifeneder ortho.production, Embla Medical issued 2,805,135 new shares on 5 September 2025. The total value of the issued shares amounted to DKK 93 million (USD 14.5 million), which the sellers subscribed to.

Proposed CMS Bidding Rule on OTS Orthoses

On 2 July 2025 CMS (US Medicare) released a proposed rule with a section dedicated to its competitive bidding program, which is designed to reduce Medicare's spending on certain types of medical devices incl. OTS orthoses. The proposed rule does not identify which orthoses will be subject to the next competitive bidding round, nor does it specify the timeline for implementation. In the past, the competitive bidding process has taken roughly 18 months. If CMS operated on the same timeline here, the earliest we would expect to see the next round go live would be sometime in 2027. As several factors remain uncertain, we believe it's still too premature to discuss potential impact at this stage.

Section 232 investigations on MedTech equipment

On 26 September 2025, the US Department of Commerce published a notice for a public consultation on a possible Section 232 Investigation concerning robotics/industrial machinery as well as personal protective equipment (PPE), medical consumables and medical equipment including devices such as hearing aids, prosthetics, orthopedic appliances, ventilators and respirators etc. The objective is to determine the effects on the US national security of imports of these goods. We are currently assessing the scope and potential implications of the Section 232 investigation and the potential trade restrictions that might result from this. As several factors remain uncertain at this stage, we deem it to be too premature to discuss potential impact until more clarity has been revealed.

ForMotion: More than halfway through unifying our Patient Care facilities under one brand

In Q3 2025 patient care facilities in selected locations in the United States were rebranded to ForMotion. Further clinics in the US and Australia are up for rebranding in Q4 2025.

Product launches during the last 12 months

Launch quarter	Segment	Product name	Product description
Q2/Q3 2025	Prosthetics Bionic foot	Odyssey® iQ (College Park)	The new Odyssey® iQ microprocessor foot is hydraulically dampened, lightweight, and low-profile. With an IP67 rating, long-lasting battery, and fast responses, it accommodates a wide range of users and activities.
Q1 2025 (Limited launch Q2 2024)	Prosthetics Bionic knee	Icon® (College Park)	Icon® features responsive sensors, streamlined setup, and the intuitive Stride Studio app. Icon® is the versatile solution for low to high activity users.
Q1 2025 (Limited launch Q2 2024)	Prosthetics Bionic knee	Navii® (Össur)	Navii® is a fully waterproof bionic knee featuring a powerful actuator provided to support consistency for stair and ramp descent. Navii® possesses a variable-position mechanical lock that can securely lock at three different angles and stay locked for standing during longer periods of time.

Conference call and financial calendar

Conference call details

Embla Medical will host a conference call on October 21, 2025, at **9:00 CET / 7:00 GMT / 3:00 ET**.

To actively participate in the telephone conference, please use the dial-in details provided below:

DK: +45 78 76 84 90

UK: +44 20 3769 6819

US: +1 646 787 0157

Participant access code: 274982

The webcast will be available through following link: [Embla Medical Q3 2025 webcast](#)

Financial calendar and events 2025

Oct 21 2025	Interim report Q3 2025
Oct 21 2025	Q3 2025 HCA Capital virtual presentation and Q&A
Oct 21 2025	Q3 2025 Investor Road Show, Copenhagen (Danske Bank)
Oct 22-23 2025	Q3 2025 Investor Road Show Benelux (DNB Carnegie)
Oct 23 2025	Q3 2025 Investor Road Show New York City (DNB Carnegie)
Nov 4 2025	Berenberg Nordic Seminar, Frankfurt
Nov 17 2025	InvestorDagen Dansk Aktionærforening, Copenhagen
Nov 18-19 2025	Jefferies Global Healthcare Conference, London
Nov 24 2025	AktiInfo Investor Event (Retail), Aalborg
Nov 25 2025	DNB Carnegie Healthcare Conference, Oslo
Nov 26 2025	HCA Capital Group presentation, Copenhagen
Nov 26 2025	Danske Bank Winter Seminar, Copenhagen
Dec 2 2025	Nordea Focus Seminar, Paris
Jan 8 2025	SEB Nordic Seminar, Copenhagen
Feb 3 2025	Interim Report Q4 2025 & 2025 Annual Report

For further information

Contact details

Klaus Sindahl, Head of Investor Relations	+45 5363 0134	ksindahl@emblamedical.com
---	---------------	---------------------------

Embla Medical corporate announcements by e-mail

If you wish to receive Embla Medical's e-mail alerts, please register on our website:

<https://emblamedical.com/investor-relations>

Forward-looking statements

This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Embla Medical hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Embla Medical hf.

**Condensed Interim Consolidated
Financial Statements**

30.09.2025

Embla Medical hf

Grjóthálsi 5

110 Reykjavík

Id-no. 560271-0189

Statement by the Board of Directors and President and CEO

The Condensed Interim Consolidated Financial Statements of Embla Medical hf. for the period from 1 January 2025 to 30 September 2025 consist of the Financial Statements of Embla Medical hf. and its subsidiaries (together referred to as “the Company” or “Embla Medical”). The Condensed Interim Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standards for Interim Financial Reporting, IAS 34, as adopted by the EU. The Condensed Interim Consolidated Financial Statements are neither audited nor reviewed by the Company's auditors.

The total Net sales of the Company amounted to USD 672.0 million and the Net profit amounted to USD 58.9 million. Total assets of the Company amounted to USD 1,721.8 million at the end of period, liabilities were USD 851.8 million and equity was USD 870.0 million.

It is our opinion that these Condensed Interim Consolidated Financial Statements present all the information necessary to give a true and fair view of the Company's financial position at 30 September 2025 and financial performance and cash flow for the period ended 30 September 2025.

The Board of Directors and the President and CEO of Embla Medical hf. hereby confirm the Condensed Interim Consolidated Financial Statements for the period from 1 January 2025 to 30 September 2025 with their signatures.

Reykjavík, 21 October 2025

Board of Directors

Niels Jacobsen
Chairman of the Board

Svafa Grönfeldt
Vice Chairman of the Board of Directors

Arne Boye Nielsen
Member of the Board of Directors

Alberto Esquenazi
Member of the Board of Directors

Tina Abild Olesen
Member of the Board of Directors

Caroline Vagner Rosenstand
Member of the Board of Directors

President and CEO

Sveinn Sölvason

Consolidated Income Statement

All amounts in USD '000	Notes	9M 2025	9M 2024	Q3 2025	Q3 2024
Net sales	3	671,998	630,108	236,795	213,528
Cost of goods sold		(251,509)	(237,526)	(88,559)	(79,916)
Gross profit		420,489	392,582	148,236	133,612
Other income / (expenses)		432	485	(382)	123
Sales and marketing expenses		(241,986)	(230,523)	(81,400)	(75,333)
Research and development expenses		(33,909)	(29,827)	(11,489)	(9,498)
General and administrative expenses		(52,162)	(51,432)	(18,065)	(16,263)
Earnings before interest and tax (EBIT)		92,864	81,285	36,900	32,641
Financial income		1,699	2,391	548	903
Financial expenses		(16,553)	(19,022)	(6,235)	(6,559)
Net exchange rate difference		(6,226)	(1,257)	1,551	485
Net financial expenses		(21,081)	(17,889)	(4,135)	(5,171)
Share in net profit of associates		5,534	2,284	1,220	668
Earnings before tax (EBT)		77,317	65,681	33,984	28,138
Income tax		(18,395)	(15,340)	(8,203)	(6,165)
Net profit		58,922	50,341	25,782	21,973
Attributable to:					
Owners of the Company		58,932	50,072	25,863	21,863
Non-controlling interests		(10)	269	(81)	110
Net profit		58,922	50,341	25,782	21,973
Earnings per share					
Basic earnings per share (US cent)		13.8	11.8	6.0	5.1
Diluted earnings per share (US cent)		13.8	11.8	6.0	5.1

Consolidated Statement of Comprehensive Income

All amounts in USD '000	9M 2025	9M 2024	Q3 2025	Q3 2024
Net profit	58,922	50,341	25,782	21,973
Items that may be reclassified subsequently to profit or loss:				
Change in cash flow hedges	(881)	631	(490)	475
Exchange difference on translating foreign operations	21,052	2,032	(426)	7,434
Income tax	4,951	838	581	1,652
Other comprehensive income, net of income tax	25,122	3,502	(335)	9,562
Total comprehensive income	84,044	53,842	25,447	31,534
Attributable to:				
Owners of the Company	84,054	53,574	25,528	31,424
Non-controlling interests	(10)	269	(81)	110
Total comprehensive income	84,044	53,842	25,447	31,534

Consolidated Balance Sheet

Assets

All amounts in USD '000	Notes	30.09.2025	31.12.2024
Property, plant and equipment	5	78,896	71,824
Right of use assets	6	157,130	127,802
Goodwill	7	836,604	776,306
Other intangible assets	8	100,153	96,645
Investment in associates		27,060	20,364
Other financial assets		4,176	2,704
Deferred tax assets		52,430	46,365
Non-current assets		1,256,449	1,142,010
Inventories		167,228	143,102
Accounts receivable		146,669	121,915
Other financial assets		593	1,475
Other assets		48,790	44,300
Cash and cash equivalents		102,074	86,163
Current assets		465,354	396,955
Total assets		1,721,803	1,538,965

Consolidated Balance Sheet

Equity and liabilities

All amounts in USD '000	30.09.2025	31.12.2024
Issued capital and share premium	101,087	93,464
Other reserves	(51,529)	(75,390)
Retained earnings	818,177	759,112
Shareholders equity	867,735	777,186
Non-controlling interest	2,239	3,513
Total equity	869,974	780,699
Borrowings	361,544	328,754
Lease liabilities	149,707	118,279
Deferred tax liabilities	36,517	37,478
Provisions	9,355	7,937
Deferred income	10,816	8,589
Other financial liabilities	30,938	47,946
Non-current liabilities	598,876	548,982
Borrowings	23,459	28,620
Lease liabilities	27,728	24,136
Accounts payable	32,855	27,275
Income tax payable	23,026	18,305
Provisions	13,109	12,615
Accrued salaries and related expenses	52,715	48,715
Other financial liabilities	35,199	10,258
Other liabilities	44,863	39,361
Current liabilities	252,953	209,284
Total liabilities	851,829	758,266
Total equity and liabilities	1,721,803	1,538,965

Consolidated Statement of Cash Flow

All amounts in USD '000	Notes	9M 2025	9M 2024	Q3 2025	Q3 2024
Earnings before interests and tax (EBIT)		92,864	81,285	36,900	32,641
Depreciation, impairment and amortization	5, 6, 8	45,118	41,337	15,950	13,927
Change in inventories		(10,635)	(5,287)	(3,857)	2,297
Change in receivables		(19,900)	(6,212)	4,038	8,141
Change in payables		4,089	(6,783)	3,076	(4,840)
Change in provisions		1,329	3,078	848	339
Other operating activities		1,664	(940)	855	(199)
Cash generated from operations		114,529	106,479	57,810	52,306
Interest received		1,670	2,367	636	1,081
Interest paid		(16,139)	(18,315)	(6,219)	(6,168)
Income tax paid		(17,831)	(16,417)	(6,005)	(5,623)
Net cash generated from operating activities		82,229	74,114	46,222	41,596
Purchase of fixed and intangible assets	5, 8	(24,277)	(31,225)	(7,882)	(8,852)
Acquisition of subsidiaries, net of cash in acquired entities	9	(3,275)	(73,971)	(3,275)	0
Payment of contingent consideration and deferred payments		(4,259)	(4,385)	0	(1,130)
Other investing activities		749	24	(902)	(77)
Cash flows used in investing activities		(31,062)	(109,557)	(12,059)	(10,059)
Proceeds from long-term borrowings		57,463	0	0	0
Repayments of long-term borrowings		(57,822)	(105)	(339)	(41)
Changes in revolving credit facility		(6,684)	61,463	(10,730)	(23,474)
Payments of lease liabilities		(20,370)	(17,941)	(6,965)	(6,198)
Increase in subsidiaries that does not affect control		(5,123)	0	(5,123)	0
Dividends from subsidiaries paid to non-controlling interests		(35)	0	(35)	0
Purchased treasury shares		(6,951)	0	(2,670)	0
Cash flows generated from financing activities		(39,522)	43,417	(25,862)	(29,713)
Net change in cash		11,645	7,974	8,301	1,824
Exchange rate effects on cash held in foreign currencies		4,266	580	(343)	2,169
Cash and cash equivalents at beginning of period		86,163	72,653	94,116	77,214
Cash and cash equivalents at end of period		102,074	81,207	102,074	81,207

Consolidated Statement of Changes in Equity

All amounts in USD '000	Share capital	Share premium	Other reserves	Retained earnings	Shareholders equity	Non-controlling interests	Total equity
Balance at 1 January 2024	4,781	61,479	(64,045)	699,667	701,883	3,123	705,005
Net profit				50,072	50,072	269	50,341
Change in cash flow hedges			505		505		505
Transl. diff. of shares in subsidiaries			2,997		2,997		2,997
Total comprehensive income	0	0	3,502	50,072	53,574	269	53,842
Share option charge for the period			826		826		826
Share option vested during the period			(1,102)	1,102	0		0
Issued new shares	48	27,156			27,205		27,205
Change in non-controlling interests				382	382	(382)	0
Balance at 30 September 2024	4,829	88,635	(60,819)	751,223	783,869	3,009	786,878
Balance at 1 January 2025	4,829	88,635	(75,390)	759,112	777,186	3,513	780,699
Net profit				58,932	58,932	(10)	58,922
Change in cash flow hedges			(705)		(705)		(705)
Transl. diff. of shares in subsidiaries			25,827		25,827		25,827
Total comprehensive income	0	0	25,122	58,932	84,054	(10)	84,044
Payment of dividends					0	(35)	(35)
Share option charge for the period			1,453		1,453		1,453
Share option vested during the period			(2,715)	2,715	0		0
Issued new shares	23	14,550			14,573		14,573
Purchase of treasury shares	(11)	(6,939)			(6,951)		(6,951)
Change in non-controlling interests				(2,581)	(2,581)	(1,229)	(3,810)
Balance at 30 September 2025	4,841	96,246	(51,529)	818,177	867,735	2,239	869,974

Notes to the Condensed Consolidated Financial Statements

1. Summary of Material Accounting Policies

Statement of compliance

The Condensed Interim Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standard (IFRS) for Interim Financial Reporting, IAS 34 as adopted by the EU. The Condensed Interim Consolidated Financial Statements are presented in accordance with the new and revised IFRS accounting standards and new interpretations (IFRIC), applicable for the period. New and amended IFRS accounting standards that are effective for the current year have minor impact on the Company's Financial Statements. The Company has not early applied new and revised IFRS accounting standards that have been issued but are not yet effective. The Financial Statements are presented in USD, which is the Company's functional currency. They do not include all of the information required for full Annual Consolidated Financial Statements and should be read in conjunction with the Company's Annual Consolidated Financial Statements for the period ended 31 December 2024. The Company's Annual Consolidated Financial Statements can be found on the Company's website www.emblamedical.com.

Basis of preparation

The Condensed Interim Consolidated Financial Statements have been prepared under the historical cost basis except for certain financial instruments that are measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The Condensed Interim Consolidated Financial Statements are presented in USD and all values are rounded to the nearest thousand ('000), except when otherwise indicated. This rounding may have impact on the total sum. The accounting policies adopted are consistent with those followed in the preparation of the Company's Annual Consolidated Financial Statements for the period ended 31 December 2024.

Notes to the Condensed Consolidated Financial Statements

2. Quarterly statements

	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024
Net sales	236,795	232,418	202,786	224,781	213,528
Cost of goods sold	(88,559)	(87,931)	(75,020)	(82,663)	(79,916)
Gross profit	148,236	144,487	127,766	142,117	133,612
Gross profit margin	63%	62%	63%	63%	63%
Other income / (expenses)	(382)	447	367	(86)	123
Sales and marketing expenses	(81,400)	(82,529)	(78,057)	(80,628)	(75,333)
Research and development expenses	(11,489)	(11,851)	(10,569)	(11,005)	(9,498)
General and administrative expenses	(18,065)	(16,817)	(17,280)	(18,532)	(16,263)
EBIT	36,900	33,737	22,227	31,867	32,641
Net financial expenses	(4,135)	(9,764)	(7,181)	(8,041)	(5,171)
Share in net profit of associates	1,220	3,701	613	1,055	668
EBT	33,984	27,674	15,659	24,882	28,138
Income tax	(8,203)	(6,561)	(3,631)	(6,263)	(6,165)
Net profit	25,782	21,113	12,027	18,619	21,973
EBITDA	52,850	48,666	36,467	46,502	46,568
EBITDA margin	22%	21%	18%	21%	22%

There were no special items in the above quarters.

3. Net Sales

	9M 2025	9M 2024	Q3 2025	Q3 2024
Sales by geographical segment:				
EMEA	326,755	294,123	112,130	96,487
Americas	291,196	286,130	104,443	99,612
APAC	54,047	49,856	20,222	17,429
Total	671,998	630,108	236,795	213,528
Sales by business segment:				
Prosthetics & Neuro Orthotics	372,468	332,473	135,345	115,019
Bracing & Supports	110,885	111,671	37,796	37,337
Internal product sales	(28,736)	(27,856)	(9,932)	(9,477)
External product sales	454,616	416,288	163,209	142,878
Patient Care	217,382	213,820	73,586	70,650
Total	671,998	630,108	236,795	213,528

Notes to the Condensed Consolidated Financial Statements

4. Sales and expenses split by main currencies

		9M 2025				Q3 2025	
	LCY	USD	%	LCY	USD	%	
Sales							
USD	260,749	260,749	39%	93,620	93,620	40%	
EUR	180,621	202,103	30%	60,994	71,212	30%	
ISK	393,951	3,042	1%	130,085	1,063	0%	
Nordic curr. (SEK, NOK, DKK)		77,004	12%		24,102	10%	
Other (GBP, AUD, CAD & Other)		129,100	19%		46,798	20%	
Total		671,998	100%		236,795	100%	
COGS and OPEX							
USD	232,993	232,993	40%	78,841	78,841	39%	
EUR	124,961	139,935	24%	44,261	51,676	26%	
ISK	8,473,276	65,319	11%	2,623,736	21,448	11%	
Nordic curr. (SEK, NOK, DKK)		73,357	13%		24,262	12%	
Other (GBP, MXN, CAD & Other)		67,529	12%		23,668	12%	
Total		579,134	100%		199,895	100%	
		9M 2024				Q3 2024	
	LCY	USD	%	LCY	USD	%	
Sales							
USD	254,112	254,112	40%	88,261	88,261	41%	
EUR	163,462	177,682	28%	54,358	59,724	28%	
ISK	361,270	2,616	0%	121,338	882	0%	
Nordic curr. (SEK, NOK, DKK)		73,402	12%		22,465	11%	
Other (GBP, AUD, CAD & Other)		122,295	19%		42,196	20%	
Total		630,108	100%		213,528	100%	
COGS and OPEX							
USD	224,402	224,402	41%	76,623	76,623	42%	
EUR	119,921	130,353	24%	39,142	43,012	24%	
ISK	8,286,042	60,032	11%	2,531,406	18,399	10%	
Nordic curr. (SEK, NOK, DKK)		67,655	12%		21,010	12%	
Other (GBP, MXN, CAD & Other)		66,381	12%		21,843	12%	
Total		548,823	100%		180,887	100%	

Currency split is derived by using best available information at each time.

Notes to the Condensed Consolidated Financial Statements

5. Property, plant and equipment

2025	Leasehold improvements	Machinery & equipment	Office equipment	Computer equipment	Total
Cost					
At 1 January	51,273	80,116	14,939	13,941	160,269
Additions	4,787	8,180	903	2,349	16,218
Business Combinations	2,212	599	58	37	2,905
Eliminated on disposal	(61)	(161)	(17)	(46)	(284)
Exchange rate differences	2,397	1,425	1,127	744	5,694
At 30 September 2025	60,607	90,159	17,010	17,026	184,803
Depreciation					
At 1 January	19,654	50,499	9,850	8,442	88,445
Charge for the period	4,305	6,042	1,212	2,753	14,311
Eliminated on disposal	(38)	(161)	(16)	(35)	(249)
Exchange rate differences	1,460	775	702	464	3,401
At 30 September 2025	25,380	57,155	11,748	11,624	105,908
At 30 September 2025	35,227	33,004	5,263	5,402	78,896
Depreciation classified by functional category:		9M 2025	9M 2024	Q3 2025	Q3 2024
Cost of goods sold		7,383	7,285	2,418	2,526
Sales and marketing expenses		3,210	3,028	1,209	932
Research and development expenses		1,000	577	376	182
General and administrative expenses		2,718	2,960	930	972
Total		14,311	13,850	4,933	4,612

Notes to the Condensed Consolidated Financial Statements

6. Leases

Right of use assets

	Buildings & sites	Machinery & equipment	Total
2025			
At 1 January	123,789	4,012	127,802
Additions and renewals	41,630	2,283	43,913
Depreciation charge and impairment for the period	(20,203)	(1,949)	(22,152)
Eliminated on disposal and termination	(1,958)	0	(1,958)
Exchange rate differences	9,023	503	9,526
At 30 September 2025	152,281	4,849	157,130

Depreciation and impairment classified by functional category:	9M 2025	9M 2024	Q3 2025	Q3 2024
Cost of goods sold	8,390	7,448	2,914	2,634
Other income / expenses	639	0	639	0
Sales and marketing expenses	6,884	3,724	2,391	1,317
Research and development expenses	2,366	2,234	822	790
General and administrative expenses	3,872	5,214	1,345	1,686
Total	22,152	18,620	8,111	6,427

At the end of the period it was decided to close two of the Company's locations. The remaining contractual payments will be settled in 2026 with relocation to the new facilities. The Company impaired the right of use assets for the related leases totaling USD 0.6 million. The corresponding lease liabilities are presented entirely as current liabilities.

7. Goodwill

	30.09.2025	31.12.2024
At 1 January	776,306	690,855
Business combinations	21,124	104,489
Exchange rate differences	39,174	(19,038)
At end of period	836,604	776,306

The goodwill increase related to current year business combination is allocated to EMEA and Americas cash generating units.

Notes to the Condensed Consolidated Financial Statements

8. Other intangible assets

2025	Customer & distribution relationships	Patents & development costs	Trademarks	Software & other	Total
Cost					
At 1 January	36,701	32,214	8,156	63,175	140,246
Additions	0	663	29	1,507	2,199
Additions - internally generated	0	0	0	5,860	5,860
Business Combinations	0	478	0	79	557
Exchange rate differences	2,973	359	703	228	4,262
At 30 September 2025	39,673	33,714	8,889	70,849	153,124
Amortization					
At 1 January	9,393	9,789	523	23,896	43,601
Charge for the period	2,536	1,728	24	4,367	8,655
Exchange rate differences	465	131	0	119	715
At 30 September 2025	12,394	11,649	547	28,382	52,971
At 30 September 2025	27,279	22,065	8,342	42,467	100,153
Amortization classified by functional category:		9M 2025	9M 2024	Q3 2025	Q3 2024
Cost of goods sold		689	1,239	215	402
Sales and marketing expenses		5,058	4,318	1,566	1,422
Research and development expenses		1,340	1,259	472	475
General and administrative expenses		1,568	2,051	653	589
Total		8,655	8,867	2,906	2,888

Notes to the Condensed Consolidated Financial Statements

9. Business combinations

On 17 July 2025 Embla Medical announced the acquisition of the majority share (51% of the shares) in the privately owned Streifeneder ortho.production GmbH ("Streifeneder"). The investment was completed on 29 August 2025 following regulatory approvals, hence one month of sales is included in Q3 Financial Statement.

Streifeneder is an international developer and supplier of orthopaedic mobility solutions, employing around 100 people. In addition to its offerings of prosthetic and orthotic components, Streifeneder also supplies orthopaedic materials and equipment to the O&P industry. In 2024, Streifeneder realized sales of EUR 25 million (approximately USD 29m) with ~70% of sales related to prosthetics and orthopaedic materials. The majority of sales are generated in Germany, while also selling into other key European markets and distributing into the Americas and APAC regions.

As part of the consideration paid for Streifeneder, Embla Medical issued 2,805,135 new shares. The share price of each share was DKK 33.26, and the total value of the share price capital increase is thus DKK 93 million (EUR 12.5 million / USD 14.5 million).

The initial accounting for the acquisition has been provisionally determined at the end of the reporting period. The goodwill is not expected to be deductible for income tax purposes.